Professional Documents
Culture Documents
Kuldip R. Marwada, Jigar B. Patel, Nisarg S. Patel, Bhargav D. Patel, Dharnant V. Borkhatariya, Archita J. Patel
Kuldip R. Marwada, Jigar B. Patel, Nisarg S. Patel, Bhargav D. Patel, Dharnant V. Borkhatariya, Archita J. Patel
Department of Quality Assurance, K.B. Institute of Pharmaceutical Education and Research, Kadi Sarva Vishwavidhyalaya, Sector-23, Gh-6, Gandhinagar, Gujarat, India
Ramanbhai Patel College of Pharmacy, CHARUSAT, Changa, Gujarat, India
h i g h l i g h t s
g r a p h i c a l a b s t r a c t
Development of chemometric
a r t i c l e
i n f o
Article history:
Received 15 October 2013
Received in revised form 30 December 2013
Accepted 3 January 2014
Available online 17 January 2014
Keywords:
Meropenem
Sulbactam sodium
Dual wavelength ultraviolet
spectrophotometric method
Chemometrics
High performance liquid chromatography
a b s t r a c t
UV spectrophotometric and high performance liquid chromatography (HPLC) methods were developed
for simultaneous determination of meropenem (MERM) and sulbactam sodium (SB) in injection. UV spectrophotometric methods were developed using 0.1 N sodium hydroxide as solvent. The Beers plot for
dual wavelength method was linear in the range of 424 lg mL1 and 212 lg mL1 for MERM and
SB, respectively. The percent recoveries were found to be 98.52 1.23% for MERM and 101.45 1.1%
for SB. Chemometrics assisted UV spectrophotometry was performed using Partial Least Square (PLS)
analysis model and Principal Component Regression (PCR) analysis model. The % recoveries of the MERM
were found to be 100.61 0.06% and 101.31 0.12% using PLS and PCR, respectively. The % recoveries of
the SB were found to be 98.29 0.09% and 97.61 0.13% using PLS and PCR, respectively. Chromatography was performed on Hypersil BDS C18 column using methanol:acetonitrile:water (10:20:70 v/v/v) as
mobile phase. The retention times of MERM and SB were found to be 2.9 min and 2.25 min, respectively.
Developed HPLC method was found to be linear in the range of 50250 lg mL1 and 25125 lg mL1 for
MERM and SB, respectively. The % recoveries were found to be 98.85 0.25% and 98.63 0.34% for MERM
and SB, respectively. The developed analytical methods did not show any interference of the excipients
when applied to pharmaceutical dosage form.
2014 Elsevier B.V. All rights reserved.
Corresponding author. Address: K.B. Institute of Pharmaceutical Education and Research, Sector 23, Near Gh-6 Circle, Gandhinagar 382023, Gujarat, India. Tel.: +91
9427458555.
E-mail addresses: kuldip_marwada@yahoo.com (K.R. Marwada), jigas2181983@gmail.com (J.B. Patel), n.nisarg@yahoo.com (N.S. Patel), bhargav.patel@live.in (B.D. Patel),
bdharanant@yahoo.com (D.V. Borkhatariya), architajpatel@gmail.com (A.J. Patel).
1386-1425/$ - see front matter 2014 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.saa.2014.01.008
K.R. Marwada et al. / Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 124 (2014) 292299
293
Introduction
Meropenem (MERM) is chemically (4R, 5S, 6S)-3-{[(3S, 5S)-5(dimethylcarbamoyl)
pyrrolidin-3-yl]
sulfanyl}-6-[(1R)-1hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo [3.2.0] hept-2-ene-2carboxylic acid (Fig. 1(A)) is a broad-spectrum carbapenem
antibiotic [1]. It is active against Gram-positive and Gram-negative
bacteria. MERM exerts its action by penetrating bacterial cells
readily and interfering with the synthesis of vital cell wall
components (inhibition of peptidoglycan synthesis), which leads
to cell death [2]. MERM is ofcial in Indian pharmacopoeia [3]
and United State Pharmacopoeia 35/National Formulary 30 [4].
Sulbactam sodium (SB) is chemically sodium (2S-cis)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0] heptane-2-carboxylate
4,4-dioxide (SB) (Fig. 1(B)) which is a competitive, irreversible
beta-lactamase inhibitor. Its binding to penicillin-binding proteins
imparts weak intrinsic antibacterial activity. SB is ofcial in British
Pharmacopoeia [5] and United States pharmacopoeia 35/National
Formulary 30 [4].
The pharmaceutical formulation (injection) of these drugs contains 1000 mg of MERM, 500 mg of SB and sodium carbonate as
excipients. This dosage form is used in severe meningitis and infection caused by Pseudomonas aeruginosa, Escherichia coli, Klebsiella
pneumoniae [6].
Based on literature review it was found that number of methods
have been reported for estimation of MERM and SB individually as
well as in combination with other drugs. The spectrophotometric
[7,8], HPLC [916], LCMS/MS [17], LCMS [18], capillary zone
electrophoresis [19] methods have been reported for estimation
of MERM and spectro-photometric [2022], RP-HPLC [2331],
HPTLC [32], LCMS [33], capillary isotachophoresis [34] methods
have been reported for estimation of SB. So far one UV spectrophotometric method [35] has been reported for simultaneous estimation of MERM and SB in the synthetic mixture, but the developed
UV method did not show any application to pharmaceutical dosage
form and it was not fully validated. Hence, an attempt was made to
develop and validate a dual wavelength and chemometrics based
UV spectrophotometric methods and RP-HPLC method for simultaneous estimation of MERM and SB in injection. All the developed
methods were compared statistically using ANOVA.
Dual wavelength spectrophotometric method is used to calculate the unknown concentration of a component of interest present
in a mixture containing another component of interest and an unwanted interfering component, by utilizing the absorbance difference at two wavelengths in spectra of the mixture. This directly
gives the concentration of the component of interest without any
interference from other components present in mixture or formulation. The basis for dual wavelength method is the selection of
two such wavelengths where the interfering component shows
same absorbance the difference in its absorbance is zero, whereas
the component of interest shows signicant concentration dependent difference in absorbances at the selected wavelengths [36].
Experimental
Materials and methods
Standards for drugs and reagents
MERM was obtained as gift sample from Montage Laboratories,
Himatnagar (Gujarat, India). SB was obtained as gift sample from
Montage Laboratories, Himatnagar (Gujarat, India) Astral pharmaceuticals, Vadodara (Gujarat, India) and Aurobindo pharma Ltd.,
(Bangalore, India). Sodium hydroxide pellets were purchased from
Finar chemicals, Vadodara (Gujarat, India). 0.1 N sodium hydroxide
solution (0.1 N) was prepared freshly in laboratory during study
using distilled water prepared in-house. HPLC grade water
294
K.R. Marwada et al. / Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 124 (2014) 292299
(Milli-Q water) was used for HPLC study. The solvents methanol
(Merck specialities Pvt. Ltd. Mumbai, India), acetonitrile (Fisher
scientic India Pvt. Ltd., Mumbai, India) were of HPLC grade.
Instruments
The dual wavelength UV spectrophotometric and chemometric
assisted UV spectrophotometric methods were developed using UV
Spectrophotometer (SHIMADZU 1800, Japan), having a pair of
10 mm matched quartz cuvettes. An analytical balance (CP 124S,
Sartorius, Germany) was used to weigh accurately the standard
and test samples. An ultrasonic bath (Fast clean, Ajmer, India)
was used for sonication. The solutions were ltered using Whatman lter paper No. 41.
The RP-HPLC method was developed using an analytical HPLC
(Analytical, PU-2080, India), Quarternary Gradient with detector
UV 2230. Milli-Q water system (Q-Guard, France) was used to prepare HPLC grade water.
Softwares
UV probe software was used in UV spectrophotometric methods
for recording spectra and absorbance. PLS_Toolbox solo demo software (Eigenvector) version 7.0.2. was used for the analysis of the
absorbance spectra by chemometric method (PLS and PCR based
regression analysis). Analchrom software was used for recording
the peaks by using RP-HPLC method.
Dual wavelength UV spectrophotometric method
Standard solutions
Accurately weighed quantity of MERM (10 mg) and SB (10 mg)
were transferred in separate 10 mL volumetric ask, dissolved in
5 mL of 0.1 N sodium hydroxide, and volume was made up to the
mark with 0.1 N sodium hydroxide (1000 lg mL1). Suitable dilution of standard stock solution was done to have concentration
of 100 lg mL1 and 50 lg mL1 of MERM and SB, respectively.
Then different aliquots were taken and suitably diluted to prepare
a mixture containing solutions in the working range of 4
24 lg mL1 of MERM and 212 lg mL1 of SB using 0.1 N sodium
hydroxide into 10 mL volumetric ask.
Sample solution
Sample solution was prepared by taking accurately weighed
quantity of powder equivalent to 10 mg of MERM and 5 mg of SB
from injection vial containing powder for injection into 10 ml volumetric ask and dissolved in 5 mL of 0.1 N sodium hydroxide.
Then volume was made up to mark using 0.1 N sodium hydroxide.
The resulting solution was appropriately diluted to get
100 lg mL1 of MERM and 50 lg mL1 of SB. From the above solution suitable dilutions were made to get nal concentration of
10 lg mL1 of MERM and 5 lg mL1 of SB using 0.1 N sodium
hydroxide.
Study of overlain spectrum and selection of wavelength
Suitable dilutions from the working standard solutions of
100 lg mL1 of MERM and 100 lg mL1 of SB were done to prepare
the solutions of MERM (8 lg mL1) and SB (8 lg mL1). The prepared solutions were scanned over the range of 200400 nm. The
wavelengths were selected on the basis of absorbance at two different wavelengths for both the drugs.
Assay of pharmaceutical formulation by dual wavelength
spectrophotometry
An accurately weighed powder from injection vial equivalent to
about 10 mg of MERM and 5 mg of SB was transferred to 10 mL
volumetric ask and dissolved in 5 mL of 0.1 N sodium hydroxide.
The volume was made up to the mark using 0.1 N sodium
Table 1
Calibration and validation (concentration) data set for chemometrics.
Sr. No.
SB
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
5
5.5
7.5
9
12
13.5
15
16.5
21
22.5
6
9
12
15
16.5
18
2.5
4
5.5
7
5
7
10
8.5
12
12
4
8
12
5
7
9
Sr. No.
SB
1
2
3
4
5
6
7
8
9
10
18
19.5
24
5.5
7.5
12.5
13.5
19.5
5.5
11.5
10
2.5
12
6
9.5
3.5
11
K.R. Marwada et al. / Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 124 (2014) 292299
P
jj
P
jj
295
296
K.R. Marwada et al. / Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 124 (2014) 292299
Fig. 5. (A) Plot of RMSEC value vs principal component number for MERM and SB
for PCR. (B) Plot of RMSEC value vs latent variable number for MERM and SB for PLS.
297
K.R. Marwada et al. / Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 124 (2014) 292299
Table 2
Results of calibration statistics obtained by chemometric analysis.
Parameters
Media
r2c
r2cv
PRESS
RMSEC
RMSECV
SEP
r2 (Correlation coefcient)
% Recovery
MERM
SB
0.996
0.996
0.40
0.186
0.280
0.020
0.997
98.29 0.09%
0.996
0.998
0.55
0.186
0.282
0.050
0.996
97.61 0.13%
Table 3
Figure of merits.
Parameters
Sensitivity
Analytical sensitivity
LOD
LOQ
Bias
MERM
SB
MERM
SB
1.01
2.62
1.26
3.81
0
1.00
6.24
0.53
1.60
0
1.005
2.57
1.28
3.89
0
1.1
6.23
0.5
1.90
0
Table 4
Optimized chromatographic conditions for HPLC.
Sr.
No.
Parameter
Chromatographic conditions
1
2
Stationary phase
Mobile phase
3
4
5
6
7
Mode of elution
Temperature
Flow rate
Injection volume
Wavelength of
detection
Fig. 8. Chromatogram of test solution of MERM (100 lg mL1) and SB (50 lg mL1).
found to be 98.85 0.25% and 98.63 0.34% for MERM and SB,
respectively. The precision of developed method was expressed
as a % of relative standard deviation (%RSD) for repeatability (%
R.S.D. values were 0.83 and 0.79 for MERM and SB, respectively),
intraday precision (% R.S.D. values were 0.90 and 0.98 for MERM
and SB, respectively), and interday precision (% R.S.D. values were
1.07 and 0.74 for MERM and SB, respectively). The LOD and LOQ
values were found to be 5.40 lg mL1 and 16.30 lg mL1 for
MERM and 3.26 lg mL1 and 9.89 lg mL1 for SB, respectively.
The robustness of the method was studied by changing the composition of mobile phase (methanol:acetonitrile:water; 9:19:72,
11:21:68, v/v/v), detection wavelength from 220 5 nm and ow
rate from 1 0.1 mL/min % R.S.D. was found to be less than 2% in
each case.
298
K.R. Marwada et al. / Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 124 (2014) 292299
Table 5
Analysis of pharmaceutical formulation containing MERM and SB by developed analytical methods.
Drug
Drug amount
RP-HPLC
PLS
PCR
MERM
10
9.95
99.50 0.13%
20
20.05
100.28 0.32%
20
20.31
101.57 0.45%
100
98.12
98.12 0.25%
SB
5
4.86
97.36 0.24%
10
9.82
98.2 0.39%
10
9.872
98.72 0.28%
50
47.28
97.5 0.51%
Table 6
Summary of comparison of the developed analytical methods by single factor ANOVA.
Anova: Single factor
Methods
Count
Sum
Average
Variance
Summary
Dual wavelength method
PLS analysis
PCR analysis
RP-HPLC method
2
2
2
2
196.86
198.48
200.29
195.62
98.43
99.24
100.15
97.81
2.29
2.16
4.06
0.19
Source of variation
SS
df
MS
P-value
F crit
ANOVA
Between methods
Within methods
Total
6.15
8.71
14.86
3
4
7
2.05
2.18
0.94
0.50
6.59
References
[1] O.M.J. Neil, The Merck Index, An Encyclopaedia of Chemicals Drugs and
Biologicals, fourteenth ed., vol. 5899, Merck Research Laboratories, USA, 2004.
p. 8885.
[2] A.G. Gilman, J.G. Hardman, L.E. Limbard, Goodman and Gilmans The
Pharmacological Basis of Therapeutics, eleventh ed., McGraw Hill Publishers,
New York, 2001. pp. 11511152.
[3] Indian Pharmacopoeia, Government of India, Ministry of Health and Family
Welfare, The Indian Pharmacopoeial Commission, Ghaziabad, vol. 2, 2010, p.
164.
[4] United State Pharmacopoeia 35/National Formulary 30, United State
Pharmacopoial Convention Inc., Washington, DC, vol. 3, 2012, p. 4699.
[5] British Pharmacopoeia, British Pharmacopoeial Commission, London, vol. 2,
2010, 2003, 2004.
[6] K.D. Tripathi, Essential of Medical Pharmacology, sixth ed., Jaypee Brothers
Medical Publisher (p) Ltd., New Delhi, 2010. 703, 709.
[7] A. Mendez, M. Steppe, E. Schapoval, J. Pharm. Biomed. Anal. 33 (2003) 947
954.
[8] N. Elragehy, E. Abdel-Moety, N. Hassan, M. Rezk, Talanta 77 (2008) 2836.
[9] Indian Pharmacopoeia, Government of India, Ministry of Health and Family
Welfare, The Indian Pharmacopoeial Commission, Ghaziabad, vol. 2, 2010, 164,
pp. 725727.
[10] S. Bompadrea, L. Ferrantea, M. Martinisb, L. Leone, J. Chromatogr. A 812 (1998)
249253.
[11] K. Ikeda, K. Ikawa, N. Morikawa, M. Miki, S. Nishimura, M. Kobayashi, J.
Chromatogr. B 856 (2007) 371375.
[12] R. Denooz, C. Charlier, J. Chromatogr. B 864 (2008) 161167.
[13] T. Legrand, S. Chhun, E. Rey, B. Blanchet, J. Zahar, F. Lanternier, G. Pons, V.
Jullien, J. Chromatogr. B 875 (2008) 551556.
[14] S.Y. Cai, C.Q. Hu, J. Pharm. Biomed. Anal. 37 (2005) 585589.
[15] U. Nandi, A. Das, S. Bachar, T. Pal, IJPIs J. Anal. Chem. 1 (6) (2011) 2330.
[16] K. Kameda, K. Ikawa, K. Ikeda, N. Morikawa, A. Nakashima, H. Ohge, T. Sueda, J.
Chromatogr. Sci. 48 (2010) 406411.
[17] G. Lin, H. Zhang, F. Xue, W. Li, N. Liu, L. Chen, X. Wang, R. Xu, J. Ma, Latin Am. J.
Pharm. 30 (10) (2011) 18951900.
[18] M.C. Wolkowiez, N.R. White, A. Bridges, D.K. Benjamin, A.D.M. Kashuba, J.
Chromatogr. B 879 (2011) 34973506.
[19] Y. Mrestani, R. Neubert, F. Nagel, J. Pharm. Biomed. Anal. 20 (1999) 899903.
[20] M.D. Raut, S.P. Ghode, R.S. Kale, M.V. Puri, H.S. Patil, Int. J. ChemTech Res. 3 (3)
(2011) 15061510.
[21] S. Durairaj, T. Annadurai, B. Palanikumar, S. Arunkumar, Int. J. ChemTech Res. 2
(4) (2010) 21772181.
[22] D.H. Prajapati, D.B. Patel, Int. J. Uni. Pharm. Life Sci. 2 (2) (2012) 6271.
[23] United State Pharmacopoeia 35/National Formulary 30, United State
Pharmacopoial Convention Inc., Washington, DC, vol. 3, 2012, p. 4699.
K.R. Marwada et al. / Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 124 (2014) 292299
[24] B. Dhandapani, N. Thirumoorthy, H. Shaik, M. Kotaiah, Int. J. ChemTech Res. 2
(1) (2010) 752755.
[25] M. Siddiqui, A. Tariq, K. Reddy, P. Negi, J. Yadav, A. Bhatnagar, M. Chaudhary, R.
Singh, Int. J. Pharmacol. 6 (2) (2010) 271277.
[26] K. Vinodkumar, J. Dharuman, A. Karunasree, Int. J. Pharm. Biosci. 1 (4) (2010)
8792.
[27] D.B. Gomis, N.S. Nunez, E.A. Garcia, M.B. Jasanada, Anal. Chim. Acta 498 (2003)
18.
[28] Y. Guillaume, E. Peyrin, C. Guinchard, J. Chromatogr. B 665 (1995) 363371.
[29] Q. Pei, G.P. Yang, Z.J. Li, X.D. Peng, J.H. Fan, Z.Q. Liu, J. Chromatogr. B 879 (2011)
20002004.
[30] P. Wang, M. Qi, Y. Sun, J. Yang, J. Pharm. Biomed. Anal. 36 (2004) 565569.
[31] G. Fredj, M. Paillet, F. Aussel, A. Brouard, H. Barreteau, C. Divine, J. Chromatogr.
B 383 (1986) 218222.
[32] R.K. Nanda, V.V. Bhagwat, S.E. Potawale, S.C. Hamane, J. Pharm. Res. 3 (7)
(2010) 16671669.
[33] Y. Zhou, J. Zhang, B. Guo, J. Yu, Y. Shi, M. Wang, Y. Zhang, J. Chromatogr. B 878
(2010) 31193124.
[34] I. Jelinek, V. Rejholec, V. Hola, Z. Roubal, Cesk Farm. 39 (7) (1990) 305307.
[35] N. Patel, F. Tandel, S. Shah, M. Patel, A. Patel, Curr. Pharm. Res. 2 (2) (2012)
480486.
[36] J. Jain, R. Patadia, D. Vanparia, R. Chauhan, S. Shah, Int. J. Pharm. Pharm. Sci. 2
(4) (2010) 7679.
[37] M.A. Sharaf, D.L. Illman, B.R. Kowalski, Chemometrics, Chemical Analysis
Series, Wiley Interscience, New York, 1986. p. 82.
[38] D.L. Massart, B.G.M. Vandeginste, S.N. Deming, Y. Michotte, L. Kaufmann,
Chemometrics A Textbook, Elsevier, Amsterdam, 1988.
[39] S. Wold, A. Ruhe, H. Wold, W.J. Dunn III, SIAM J. Sci. Stat. Comput. 5 (1984)
735743.
[40] M. Sjostrom, S. Wold, W. Lindberg, J.A. Persson, H. Martens, Anal. Chim. Acta
150 (1983) 6170.
[41] S. Wold, C. Albano, W.J. Dunn III, K. Esbensen, S. Hellberg, E. Johansson, et al.,
Pattern recognition: nding and using regularities in multivariate data, in: H.
Martens, H. Russworm Jr. (Eds.), Food Research and Data Analysis, Applied
Science Publishers, London, 1983, pp. 147188.
299